Posted by Jeff Wilder on Feb 6th, 2026
Immunic, Inc. (NASDAQ:IMUX – Get Free Report) has been assigned a consensus recommendation of “Buy” from the nine analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst...
More of this article »